Rani Therapeutics Holdings, Inc. (RANI) intrinsic value & 10-year financials
Rani Therapeutics Holdings, Inc. (RANI) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 6 fiscal years revenue grew 28.7% a year to $1.6M, with an average return on invested capital of -10.2%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.64
- Market cap
- $42.4K
- Revenue (FY2025)
- $1.6M
- Revenue growth (6-yr CAGR)
- 28.7%
- ROIC (10-yr avg)
- -10.2%
- Free cash flow (FY2025)
- -$18.8M
RANI 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $1.6M | -$29.7M | -$0.45 | -$18.8M | -2346.0% | -175.7% |
| FY2024 | $1.0M | -$30.0M | -$1.05 | -$35.8M | -5186.2% | -169.6% |
| FY2023 | $0 | -$34.0M | -$1.33 | -$52.5M | — | -175.2% |
| FY2022 | $0 | -$30.6M | -$1.28 | -$48.1M | — | 409.5% |
| FY2021 | $2.7M | -$8.3M | -$0.43 | -$32.8M | -1899.1% | 40.8% |
| FY2020 | $462.0K | -$16.7M | — | -$16.2M | -3581.0% | 9.1% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Rani Therapeutics Holdings, Inc. is a consistent compounder, expanding top-line revenue at 28.7% annually over the past decade.
Rani Therapeutics Holdings, Inc. returns on capital have been average, hovering around 8.1% ROIC over the decade.
Over the decade, Rani Therapeutics Holdings, Inc. shows that the company has leveraged its balance sheet to sustain operations.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Rani Therapeutics Holdings, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-14.95 per share.